Skip to content
HowShorted

BIOCRYST PHARMACEUTICALS INC short interest in 2019

In 2019, BIOCRYST PHARMACEUTICALS INC's disclosed short interest ran from 9.15% of shares outstanding on 15 Jan 2019 to 16.30% on 31 Dec 2019, a change of +7.15 percentage points. The year's high was 16.30% on 31 Dec 2019 and its low 8.50% on 15 Feb 2019, averaging 11.32% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.22 days on 29 Mar 2019. Full history: BIOCRYST PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for BIOCRYST PHARMACEUTICALS INC in 2019

2019 in figures

Start of year
9.15% (15 Jan 2019)
End of year
16.30% (31 Dec 2019)
Change
+7.15 pp
High
16.30% (31 Dec 2019)
Low
8.50% (15 Feb 2019)
Average
11.32%
Highest days to cover
20.22 (29 Mar 2019)
SEC filings marked
8

Every report in 2019

BIOCRYST PHARMACEUTICALS INC short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20199.15%13.84
31 Jan 20198.81%13.01
15 Feb 20198.50%15.69
28 Feb 20198.73%15.12
15 Mar 20198.95%9.35results (8-K), 10-K filed
29 Mar 20199.73%20.22
15 Apr 20199.02%8.95
30 Apr 20199.53%12.27
15 May 201910.83%11.92results (8-K), 10-Q filed
31 May 201910.07%1.73
14 Jun 20199.02%4.38
28 Jun 201911.40%6.13
15 Jul 201912.02%11.38
31 Jul 201910.89%9.05
15 Aug 201911.83%10.46results (8-K), 10-Q filed
30 Aug 201913.30%10.46
13 Sep 201913.55%11.57
30 Sep 201913.47%6.58
15 Oct 201912.62%12.96
31 Oct 201914.26%10.81
15 Nov 201916.25%5.68results (8-K), 10-Q filed
29 Nov 201911.03%2.53
13 Dec 201912.41%4.34
31 Dec 201916.30%7.46

See also: BIOCRYST PHARMACEUTICALS INC's full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.